medigraphic.com

2010, Number 4

<< Back Next >>

Med Sur 2010; 17 (4)

Gadolinium nephrogenic systemic fibrosis

Carrillo ER, Carrillo CCA, Motola KM

Language: English
References: 22
Page: 186-189
PDF size: 76.46 Kb.


ABSTRACT

Nephrogenic systemic fibrosis (NSF) was described in 1997. Is a disease linked to the use of gadolinium based contrast agents. NSF is a debilitating fibrosing disorder that develops in patients with underlying kidney disease exposed to gadolinium. Clinical manifestations are cutaneous hyperpigmentation and induration and joint contractures. Fibrosis may also develop in other organs like skeletal muscle, liver, lung and heart. The mortality can reach 31%. Current management is disappointing. In all patients with elevated serum creatinine physicians should estimate his kidney function in order to ensure the safety of magnetic resonance imaging. Prevention with hemodialysis immediately following gadolinium-based contrast agents has been recommended. Physicians should use alternative imaging modalities for patients who are at risk.


REFERENCES

  1. Fibrosing skin condition among patients with renal disease. United States and Europe, 1997-2002. MMWR Morb Mortal Wkly Rep 2002; 51: 25-30

  2. LeBoit PE. What nephogenic fibrosing dermopathy might be? Arch Dermatol 2003; 139: 928-30.

  3. Deo A, Fogel M, Cowper SE. Nephogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephol 2007; 2: 264-7.

  4. The International Center for Nephogenic Fibrosing Dermopathy Research. http://www.icnfdr.org (access October 24, 2010)

  5. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 2006; 24: 445-51.

  6. Golding LP, Provenzale JM. Nephogenic systemic fibrosis: possible association with a predisposing infection. Am J Roentenol 2000; 190: 1069-72.

  7. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007; 7: 2425-32.

  8. Mendoza FA, Artlett CM, Sandofi N. Description of 12 cases of nephogenic fibrosing dermopathy and review of the literature. Semin Arthitis Rheum 2006; 35: 238-43.

  9. Wermuth PJ, Del Galdo F, Jimenez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monociytes by gadolinium contrast agents. Arthiritis Rheum 2009; 60: 1508-18.

  10. Bellin MF. MR contrast agents, the old and the new. Eur J Radiol 2006; 60: 314-23.

  11. Galan A, Cowper SE, Bucala R. Nephogenic systemic fibrosis. Curr Opin Rheumatol 2006; 18: 614-17.

  12. Bangsgaard N, Marckmann P, Rosen K, Skov L. Nephogenic systemic fibrosis: late skin manifestations. Arch Dermatol 2009; 145: 183-7.

  13. Levine JM, Taylos RA, Elman LB. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephogenic fibrosing dermopathy). Muscle Nerve 2004; 30: 369-77.

  14. Daram SR, Cortese CM, Bastani B. Nephogenic fibrosing dermopathy/ nephogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005; 46: 754-9.

  15. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56: 27-30.

  16. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and aptients undergoing hemodialysis or continupus ambulatory peritoneal dialysis. Acad Radio 1998; 5: 491-502.

  17. Murashima M, Drott H, Carlow D, Shaw LM, Milone M, Bachman M, et al. Removal of gadolinium by peritoneal dyalisis. Clin Nephol 2008; 69: 368-72.

  18. Gillet M, Cossio A, Burg G, Nestle OF. Successful treatment of thee cases of nephogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005; 152: 531-6.

  19. Fisher GJ, Datta S, Wang Z. c-Jun dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest 2000; 106: 663-70.

  20. Kay J, High WA. Imatinib mesylate treatment of nephogenic systemic fibrosis. Arthitis Rheum 2008; 58: 2543-8.

  21. Schoeder JA, Weingart C, Corsa B. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephol 2008; 3: 968-75.

  22. Chung HJ, Chung KY. Nephogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 2004; 150: 596-7.




2020     |     www.medigraphic.com